Literature DB >> 171226

Nasopharyngeal carcinoma. IX. Antibodies to EBNA and correlation with response to other ebv antigens in chinese patients.

G de-Thé, J H Ho, D V Ablashi, N E Day, A J Macario, M C Martin-Berthelon, G Pearson, R Sohier.   

Abstract

Ninety-five sera from Chinese NPC patients in different stages of the disease, 38 sera from Chinese patients with other cancers, and 50 normal Chinese sera, were titrated for EBNA, VCA, EA and complement-fixing (CF/S) EBV-specific antibodies. The geometric mean (GMT) EBNA antibody titre of patients with NPC at stage I was found to be four times higher than that of normal individuals and increased in parallel with clinical deterioration. Antibody titres against EBNA did not correlate with either VCA or EA antibodies but, in general, correlated with CF/S antibodies. EA antibodies correlated relatively well with VCA antibodies and discriminated better than EBNA titre between NPC at stage I and controls.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 171226     DOI: 10.1002/ijc.2910160503

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  14 in total

1.  Characterization of Epstein-Barr virus antigens. I. Biochemical analysis of the complement-fixing soluble antigen and relationship with Epstein-Barr virus-associated nuclear antigen.

Authors:  G Lenoir; M C Berthelon; M C Favre; G de-Thé
Journal:  J Virol       Date:  1976-02       Impact factor: 5.103

2.  Nasopharyngeal and adjacent neoplasms: a clinico-pathologic and immunologic study.

Authors:  C Uhlmann; G R Krueger; K Sesterhenn; K G Rose; D V Ablashi; F Wustrow
Journal:  Arch Otorhinolaryngol       Date:  1978-01-30

3.  The capsid antigen of Epstein-Barr virus in nasopharyngeal carcinomas: comparison of serum antibody titre, cellular antigen content and histopathology.

Authors:  N Falser
Journal:  Arch Otorhinolaryngol       Date:  1984

4.  Experimental studies on specific immunotherapy in nasopharyngeal carcinoma (NPC).

Authors:  W Arnold; K H Vosteen
Journal:  Arch Otorhinolaryngol       Date:  1980

5.  Superinfection epithelial nasopharyngeal carcinoma cells with Epstein-Barr virus.

Authors:  R Glaser; G de Thé; G Lenoir; J H Ho
Journal:  Proc Natl Acad Sci U S A       Date:  1976-03       Impact factor: 11.205

6.  Frequency and levels of antibodies to Epstein-Barr virus-specific DNase are elevated in patients with nasopharyngeal carcinoma.

Authors:  Y C Cheng; J Y Chen; R Glaser; W Henle
Journal:  Proc Natl Acad Sci U S A       Date:  1980-10       Impact factor: 11.205

7.  Induction of Epstein-Barr virus nuclear antigen and DNA synthesis in a human epithelial cell line after Epstein-Barr virus infection.

Authors:  H Ben-Bassat; S Mitrani-Rosenbaum; N Goldblum
Journal:  J Virol       Date:  1982-02       Impact factor: 5.103

8.  Epstein-Barr-virus-specific IgA and IgG serum antibodies in nasopharyngeal carcinoma.

Authors:  H C Ho; M H Ng; H C Kwan; J C Chau
Journal:  Br J Cancer       Date:  1976-12       Impact factor: 7.640

9.  Cold lymphocytotoxic antibodies in nasopharyngeal carcinoma.

Authors:  J P Lamelin; J P Revillard; J M Chalopin; J H Ho; T Souissi; G Schwaab; G De-Thé
Journal:  Br J Cancer       Date:  1977-04       Impact factor: 7.640

10.  In vitro immune responses to PPD, extracts from Raji cells and nasopharyngeal carcinoma biopsies in NPC leucocytes.

Authors:  W S Ng; M H Ng; H C Ho; J P Lamelin
Journal:  Br J Cancer       Date:  1977-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.